ClinicalTrials.Veeva

Menu

A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia

Pfizer logo

Pfizer

Status

Completed

Conditions

Covid-19

Treatments

Drug: nirmatrelvir, ritonavir

Study type

Observational

Funder types

Industry

Identifiers

NCT06016556
C4671054

Details and patient eligibility

About

The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir, ritonavir treatment.

Enrollment

250 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Confirmed COVID-19 infection during the study observation period
  • Nirmatrelvir, ritonavir written prescription

Exclusion criteria

  • None

Trial design

250 participants in 1 patient group

Patients receiving Nirmatrelvir; Ritonavir (PAXLOVID)
Description:
Adult COVID-19 patients' HCRU within the 30-day period following nirmatrelvir, ritonavir prescription.
Treatment:
Drug: nirmatrelvir, ritonavir

Trial contacts and locations

4

Loading...

Central trial contact

Pfizer CT.gov Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems